Skip to main content

6 Result(s)

within Carol Fabian Remove this filter

and

  1. No Access

    Chapter

    Risk Reduction from Weight Management and Physical Activity Interventions

    Obesity and low levels of physical activity are associated with a higher risk of breast cancer recurrence and mortality. Currently, over 65 % of breast cancer survivors are overweight or obese, and fewer than ...

    Melinda L. Irwin, Carol Fabian… in Improving Outcomes for Breast Cancer Survi… (2015)

  2. Article

    Open Access

    Cardiorespiratory fitness in breast cancer survivors

    Maximal oxygen uptake (VO2max) has been used to assess risk for all-cause mortality and cardiovascular disease (CVD), and low VO2max has recently been associated with increased mortality from breast cancer. The p...

    David Burnett, Patricia Kluding, Charles Porter, Carol Fabian… in SpringerPlus (2013)

    Download PDF (361 KB) View Article

  3. Article

    Surrogates are just surrogates, but helpful just the same

    Carol Fabian in Breast Cancer Research (2007)

    Download PDF (146 KB) View Article

  4. No Access

    Article

    Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer

    Daniel D. Von Hoff, Stephanie J. Green, James A. Neidhart… in Investigational New Drugs (1991)

  5. No Access

    Article

    Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease

    The Southwest Oncology Group has evaluated methyl-GAG on a weekly schedule among patients with lymphoma and Hodgkin's disease. Among 56 fully and partially evaluable patients responses were seen in 3 of 10 pat...

    William A. T. Knight III, Carol Fabian, John J. Costanzi… in Investigational New Drugs (1983)

  6. No Access

    Article

    Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group

    124 patients with metastatic breast cancer were entered into this phase II trial of mitoxantrone (DHAD). Patients were stratified prior to treatment as good or poor risk, and whether they had received previous...

    William A. Knight III, Daniel D. Von Hoff, James A. Neidhart… in Investigational New Drugs (1983)